Cytosorbents Corp: insider trades · United States · SEC (Form 4)

About Cytosorbents Corp

CytoSorbents Corp. is a United States-based medical technology company listed on the NASDAQ under ticker CTSO. The company operates in the blood purification and critical care device space, with a focus on intensive care, cardiac surgery, and extracorporeal adsorption therapies. Its corporate headquarters and main operating facility are in Princeton, New Jersey, while it also maintains facilities in Berlin, Germany. That footprint is important because CytoSorbents has built a meaningful commercial base in Europe while continuing to pursue regulatory and commercial opportunities in North America. The company’s core commercial product is CytoSorb, a proprietary blood purification device used primarily in intensive care and cardiac surgery settings. CytoSorb is designed to adsorb certain inflammatory mediators and other unwanted substances from the blood, making it relevant in severe inflammatory conditions, sepsis-related care, and complex perioperative use cases. In Europe, CytoSorb has CE-mark approval and remains the principal revenue driver for the company. CytoSorbents also markets VetResQ in the U.S. animal health market, expanding its reach into veterinary critical care. A key part of the investment case is DrugSorb-ATR, an investigational device in the United States and Canada. Built on equivalent polymer technology, it is intended to reduce perioperative bleeding risk in high-risk surgery patients taking blood thinners, especially in urgent cardiac surgery. CytoSorbents has been actively pursuing FDA approval for DrugSorb-ATR and has described it as a potential second growth engine if it reaches commercialization. The company also commercializes the PuriFi hemoperfusion pump in select international markets. From a market-position standpoint, CytoSorbents is a niche specialist rather than a broad-based medtech platform. Its competitive strengths come from a focused therapeutic angle, clinical evidence supporting use in select applications, and a recognized presence in Europe, where reimbursement and procedure coding have helped adoption. The company’s products address serious, high-acuity medical conditions where speed of intervention matters and treatment options can be limited. Historically, CytoSorbents was founded in the 2000s and has evolved around its proprietary adsorption technology. Over time, the business has expanded from a Europe-led commercial model into a more global platform spanning Europe, Switzerland, the United Kingdom, the U.S. animal health market, and ongoing North American regulatory efforts. Recent business updates in 2025 and 2026 show modest revenue growth, continued cost discipline, and a stated objective of reaching cash flow breakeven in the second half of 2026. Management has also highlighted ongoing FDA interactions around DrugSorb-ATR, which remains a central catalyst. For investors, CTSO is a specialized, catalyst-driven NASDAQ-listed medtech name in the United States, with upside tied to execution, reimbursement, and regulatory progress.